nach oben

Erschienen in:

11.10.2019 | Laboratory Investigation

TRIM44 is indispensable for glioma cell proliferation and cell cycle progression through AKT/p21/p27 signaling pathway

verfasst von: Xia Zhou, Yadong Yang, Pengcheng Ma, Na Wang, Dong Yang, Qiu Tu, Bin Sun, Tingxiu Xiang, Xudong Zhao, Zongliu Hou, Xiangdong Fang

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Glioma is one of the lethal cancers which needs effective therapeutic target. TRIM44 has been found playing a carcinogenic role in human tumors such as breast cancer and ovarian cancer. However, the pathophysiological significance of TRIM44 in glioma is still unclear.

Methods

Quantitative-PCR and western blot were used to assess the expression of TRIM44 in glioma cells. For cell proliferation, Brdu incorporation and colony formation assays were performed. By Caspase 3 staining and FACS analysis, we revealed that TRIM44 knockdown induced glioma cell apoptosis. A BALB/c nude mouse xenograft model and following immunohistochemical (IHC) staining enables us to explore the effect of TRIM44 deletion on glioma growth in vivo. Western blot of p21, p27 and AKT indicated the possible role of TRIM44 in regulation AKT pathway in glioma.

Results

TRIM44 was significantly elevated in glioma cells, and high expression of TRIM44 is related to poor prognostic of glioma patients. TRIM44 knockdown by shRNAs inhibit glioma cell proliferation, migration, induced cell cycle disruption and further cellular apoptosis in vitro. As well, TRIM44 inactivation obviously inhibit tumor growth in xenograft model. Furthermore, the negative cell cycle regulators p21/p27 are significantly upregulated, while AKT which is known as the main regulator of p21/p27 is inactivated in TRIM44-dificient cells. These results suggested that TRIM44 inactivation disrupted cell cycle progression and inhibit cell proliferation through AKT/p21/p27 pathway in glioma.

Conclusion

TRIM44 was associated with oncogenic potential of glioma. Targeting TRIM44 might be beneficial for glioma therapy.

Nur mit Berechtigung zugänglich

Loeper S, Romeike BFM, Heckmann N, Jung V, Henn W, Feiden W et al (2001) Frequent mitotic errors in tumor cells of genetically micro-heterogeneous glioblastomas. Cytogenet Cell Genet 94(1–2):1–8PubMed

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97–109PubMedPubMedCentral

Kuhnt D, Becker A, Ganslandt O, Bauer M, Buchfelder M, Nimsky C (2011) Correlation of the extent of tumor volume resection and patient survival in surgery of glioblastoma multiforme with high-field intraoperative MRI guidance. Neuro Oncol 13(12):1339–1348PubMedPubMedCentral

Jovcevska I, Kocevar N, Komel R (2013) Glioma and glioblastoma—how much do we (not) know? Mol Clin Oncol 1(6):935–941PubMedPubMedCentral

Wei J, Gabrusiewicz K, Heimberger A (2013) The controversial role of microglia in malignant gliomas. Clin Dev Immunol. https://doi.org/10.1155/2013/285246 CrossRefPubMedPubMedCentral

Kesari S, Schiff D, Henson JW, Muzikansky A, Gigas DC, Doherty L et al (2008) Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro Oncol 10(3):300–308PubMedPubMedCentral

Werner MH, Phuphanich S, Lyman GH (1995) The increasing incidence of malignant gliomas and primary central-nervous-system lymphoma in the elderly. Cancer 76(9):1634–1642PubMed

Baumann F, Bjeljac M, Kollias SS, Baumert BG, Brandner S, Rousson V et al (2004) Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme. J Neurooncol 67(1–2):191–200PubMed

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996PubMed

10.

Boutou E, Matsas R, Mamalaki A (2001) Isolation of a mouse brain cDNA expressed in developing neuroblasts and mature neurons. Brain Res Mol Brain Res 86(1–2):153–167PubMed

11.

Carthagena L, Bergamaschi A, Luna JM, David A, Uchil PD, Margottin-Goguet F et al (2009) Human TRIM gene expression in response to interferons. PLoS ONE 4(3):e4894PubMedPubMedCentral

12.

Ozato K, Shin DM, Chang TH, Morse HC (2008) TRIM family proteins and their emerging roles in innate immunity. Nat Rev Immunol 8(11):849–860PubMedPubMedCentral

13.

Meroni G, Diez-Roux G (2005) TRIM/RBCC, a novel class of 'single protein RING finger' E3 ubiquitin ligases. BioEssays 27(11):1147–1157PubMed

14.

Yang B, Wang J, Wang Y, Zhou H, Wu X, Tian Z et al (2013) Novel function of Trim44 promotes an antiviral response by stabilizing VISA. J Immunol 190(7):3613–3619PubMed

15.

Zhu X, Wu Y, Miao X, Li C, Yin H, Yang S et al (2016) High expression of TRIM44 is associated with enhanced cell proliferation, migration, invasion, and resistance to doxorubicin in hepatocellular carcinoma. Tumour Biol 37(11):14615–14628PubMed

16.

Kashimoto K, Komatsu S, Ichikawa D, Arita T, Konishi H, Nagata H et al (2012) Overexpression of TRIM44 contributes to malignant outcome in gastric carcinoma. Cancer Sci 103(11):2021–2026PubMedPubMedCentral

17.

Peters CJ, Rees JRE, Hardwick RH, Hardwick JS, Vowler SL, Ong CAJ et al (2010) A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia. Gastroenterology 139(6):1995–U280PubMed

18.

Xing Y, Meng Q, Chen X, Zhao Y, Liu W, Hu J et al (2016) TRIM44 promotes proliferation and metastasis in nonsmall cell lung cancer via mTOR signaling pathway. Oncotarget 7(21):30479–91PubMedPubMedCentral

19.

Luo Q, Lin H, Ye X, Huang J, Lu S, Xu L (2015) Trim44 facilitates the migration and invasion of human lung cancer cells via the NF-kappaB signaling pathway. Int J Clin Oncol 20(3):508–17PubMed

20.

Kawabata H, Azuma K, Ikeda K, Sugitani I, Kinowaki K, Fujii T et al (2017) TRIM44 is a poor prognostic factor for breast cancer patients as a modulator of NF-kappaB signaling. Int J Mol Sci. https://doi.org/10.3390/ijms18091931 CrossRefPubMedPubMedCentral

21.

Ong CA, Shannon NB, Ross-Innes CS, O'Donovan M, Rueda OM, Hu DE et al (2014) Amplification of TRIM44: pairing a prognostic target with potential therapeutic strategy. J Natl Cancer Inst. https://doi.org/10.1093/jnci/dju050 CrossRefPubMedPubMedCentral

22.

Li L, Shao MY, Zou SC, Xiao ZF, Chen ZC (2019) MiR-101-3p inhibits EMT to attenuate proliferation and metastasis in glioblastoma by targeting TRIM44. J Neurooncol 141(1):19–30PubMed

23.

Wang X, Gao P, Long M, Lin F, Wei JX, Ren JH et al (2011) Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol 28(4):1225–54PubMed

24.

Fillies T, Woltering M, Brandt B, Van Diest JP, Werkmeister R, Joos U et al (2007) Cell cycle regulating proteins p21 and p27 in prognosis of oral squamous cell carcinomas. Oncol Rep 17(2):355–9PubMed

25.

Somasundaram K, Zhang HB, Zeng YX, Houvras Y, Peng Y, Zhang HX et al (1997) Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21(WAF1/CiP1). Nature 389(6647):187–90PubMed

26.

Polyak K, Lee MH, Erdjumentbromage H, Koff A, Roberts JM, Tempst P et al (1994) Cloning of P27(Kip1), a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78(1):59–66PubMed

27.

Longo PA, Kavran JM, Kim MS, Leahy DJ (2013) Transient mammalian cell transfection with polyethylenimine (PEI). Methods Enzymol 529:227–40PubMedPubMedCentral

28.

Geraerts M, Willems S, Baekelandt V, Debyser Z, Gijsbers R (2006) Comparison of lentiviral vector titration methods. BMC Biotechnol 6:34PubMedPubMedCentral

29.

Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J et al (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63(18):5821–8PubMed

30.

Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, Russell R et al (2009) Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 4(6):568–80PubMed

31.

Euhus DM, Hudd C, LaRegina MC, Johnson FE (1986) Tumor measurement in the nude mouse. J Surg Oncol 31(4):229–34PubMed

32.

Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA (2010) Multicellular tumor spheroids: An underestimated tool is catching up again. J Biotechnol 148(1):3–15PubMed

33.

Tiwary S, Xu L (2016) FRIZZLED7 is required for tumor inititation and metastatic growth of melanoma cells. PLoS ONE 11(1):e0147638PubMedPubMedCentral

34.

Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P et al (1994) Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78(1):59–66PubMed

35.

Lu S, Ren CX, Liu Y, Epner DE (2006) PI3K-Akt signaling is involved in the regulation of p21(WAF/CIP) expression and androgen-independent growth in prostate cancer cells. Int J Oncol 28(1):245–51PubMed

36.

Li Y, Dowbenko D, Lasky LA (2002) AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival. J Biol Chem 277(13):11352–61PubMed

37.

Prasad SB, Yadav SS, Das M, Modi A, Kumari S, Pandey LK et al (2015) PI3K/AKT pathway-mediated regulation of p27(Kip1) is associated with cell cycle arrest and apoptosis in cervical cancer. Cell Oncol (Dordrecht) 38(3):215–25

38.

Krakhmal NV, Zavyalova MV, Denisov EV, Vtorushin SV, Perelmuter VM (2015) Cancer invasion: patterns and mechanisms. Acta Nat 7(2):17–28

39.

Gao CF, Xie Q, Su YL, Koeman J, Khoo SK, Gustafson M et al (2005) Proliferation and invasion: plasticity in tumor cells. Proc Natl Acad Sci USA 102(30):10528–33PubMedPubMedCentral

40.

Liu Y, Zhang X, Wang J, Yang J, Tan WF (2015) JNK is required for maintaining the tumor-initiating cell-like properties of acquired chemoresistant human cancer cells. Acta Pharmacol Sin 36(9):1099–106PubMedPubMedCentral

41.

Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C (2006) Clonogenic assay of cells in vitro. Nat Protoc 1(5):2315–9PubMed

42.

Rajendran V, Jain MV (2018) In vitro tumorigenic assay: colony forming assay for cancer stem cells. Methods Mol Biol 1692:89–95PubMed

43.

Wang L, Chen QX, Chen ZB, Tian DF, Xu HT, Cai Q et al (2015) EFEMP2 is upregulated in gliomas and promotes glioma cell proliferation and invasion. Int J Clin Exp Pathol 8(9):10385–93PubMedPubMedCentral

44.

Gutschner T, Diederichs S (2012) The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol 9(6):703–19PubMedPubMedCentral

45.

Kunter I, Erdal E, Nart D, Yilmaz F, Karademir S, Sagol O et al (2014) Active form of AKT controls cell proliferation and response to apoptosis in hepatocellular carcinoma. Oncol Rep 31(2):573–80PubMed

46.

Yu JSL, Cui W (2016) Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination. Development 143(17):3050–60PubMed

47.

Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P et al (1996) Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 15(23):6541–51PubMedPubMedCentral

48.

Wan X, Helman LJ (2003) Levels of PTEN protein modulate Akt phosphorylation on serine 473, but not on threonine 308, in IGF-II-overexpressing rhabdomyosarcomas cells. Oncogene 22(50):8205–11PubMed

49.

Xiong D, Jin C, Ye X, Qiu B, Jianjun X, Zhu S et al (2018) TRIM44 promotes human esophageal cancer progression via the AKT/mTOR pathway. Cancer Sci 109(10):3080–92PubMedPubMedCentral

Titel: TRIM44 is indispensable for glioma cell proliferation and cell cycle progression through AKT/p21/p27 signaling pathway
verfasst von: Xia Zhou
Yadong Yang
Pengcheng Ma
Na Wang
Dong Yang
Qiu Tu
Bin Sun
Tingxiu Xiang
Xudong Zhao
Zongliu Hou
Xiangdong Fang
Publikationsdatum: 11.10.2019
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 2/2019
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-019-03301-0

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

Risk factors for intraoperative stimulation-related seizures during awake surgery: an analysis of 109 consecutive patients

Oligodendroglioma confers higher risk of radiation necrosis

Intraoperative radiotherapy (IORT) for surgically resected brain metastases: outcome analysis of an international cooperative study

Increasing value of autopsies in patients with brain tumors in the molecular era

Long term results of primary radiosurgery for vestibular schwannomas